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Abstract
Overexpression of the retroviral oncoprotein v-Rel can rapidly transform and immortalize a variety of avian cells in culture. However,
mammalian models for v-Rel-mediated oncogenesis have been compromised by the fact that high-level expression of v-Rel has been
reported to be toxic in many mammalian cell types, including mouse 3T3 cells, Rat-1 cells, and mouse bone marrow cells. In this article,
we demonstrate that 3T3 cells can support expression of v-Rel for at least 24 days when infected with a mouse stem cell virus (MSCV)
retroviral vector containing v-rel. In retrovirus-infected 3T3 cells, v-Rel is located in the nucleus and can bind to DNA, but does not
transform the cells. On the other hand, 3T3 and Rat-2 cells do not express v-Rel after stable transfection with a pcDNA-based v-Rel
expression vector. We also show that infection of the IL3-dependent mouse B cell line BaF3 with the MSCV-v-rel vector results in
expression of v-Rel, but does not convert these cells to growth factor independence. In contrast to 3T3 cells, the dog osteosarcoma D17 cell
line can support a high level of v-Rel expression, after either transfection or infection with a retroviral vector. That is, v-Rel can be stably
expressed as a nuclear, DNA-binding protein in D17 cells to approximately the same level as in chicken embryo fibroblasts. These results
suggest that the restriction to v-Rel expression in rodent fibroblasts is generally absent in D17 cells and that the type of v-rel expression
vector determines whether 3T3 cells can support stable expression of v-Rel. The findings reported here are an essential first step in the
development of mammalian systems to study Rel-mediated oncogenesis.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The retroviral oncoprotein v-Rel, encoded by the highly
oncogenic avian Rev-T retrovirus, is a transcription factor in
the Rel/NF-B family (reviewed in Gilmore, 1999b). v-Rel
causes rapidly fatal lymphoid cell malignancies in young
birds and efficiently transforms and immortalizes a variety
of avian lymphoid cells in tissue culture. The oncogenicity
of v-Rel is dependent on its ability to form homodimers,
bind to DNA, and activate transcription. That is, mutations
in v-Rel that abolish or diminish any one of these activities
correspondingly affect the transforming activity of v-Rel.
The vertebrate cellular Rel/NF-B family includes p50/
p105, p52/p100, c-Rel, Re1A (p65), and RelB (Gilmore,
1999a). These proteins can, with few exceptions, form ho-
modimers and heterodimers, which bind to specific target
DNA sites to influence the expression of a wide variety of
genes involved in many cellular processes (Pahl, 1999; see
also www.nf-kb.org). In most normal cell types, Rel/NF-B
dimers reside primarily in the cytoplasm in a latent, inactive
state, by virtue of their interaction with IB inhibitor pro-
teins (reviewed in Silverman and Maniatis, 2001).
In several settings, cellular Rel/NF-B transcription fac-
tors have also been associated with human oncogenesis
(reviewed in Gilmore et al., 2002). First, in many tumor cell
types, there is constitutively nuclear and active NF-B.
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Second, in several human lymphoid cancers, amplifications,
chromosomal rearrangements, and point mutations have
been detected in genes encoding Rel/NF-B or IB factors.
Third, overexpression of wild-type human c-Rel can malig-
nantly transform primary chicken spleen cells (Gilmore et
al., 2001).
Despite its acute oncogenicity in avian cells, v-Rel has
not been reported to transform any mammalian cell type in
tissue culture. Moreover, v-Rel and the closely related
chicken c-Rel have been shown to be toxic in many mam-
malian cells, including mouse and chicken bone marrow
cells (Abbaddie et al., 1993; Schwartz and Witte, 1988),
3T3 cells (Ge´linas and Temin, 1988), Rat-1 cells (Ge´linas
and Temin, 1988; Hannink and Temin, 1989), and HeLa
cells (Bash et al., 1997). Transgenic mice in which v-rel is
under the control of the T cell specific lck promoter do
develop T cell leukemias (Carrasco et al., 1996). However,
these malignancies take a long time to arise, suggesting that
multiple mutagenic events have occurred in the cells; fur-
thermore, malignant T cells from these mice grow poorly in
cell culture and cannot be established (Carrasco et al.,
1996). Thus, mammalian cell-culture model systems for
studying the role of Rel/NF-B factors in oncogenesis are
lacking, and essentially nothing is known about the basis or
potential for v-Rel-mediated toxicity in mammalian cells.
In this article, we show that mouse 3T3 cells can support
expression of nuclear v-Rel when its expression is directed
by a retroviral vector, but not by a plasmid vector. In
contrast, the dog osteosarcoma D17 cell line can tolerate
high-level expression of nuclear v-Rel, whether introduced
on plasmid or retroviral vectors. Although v-Rel does not
transform mouse fibroblasts or a mouse pro-B cell line, the
results presented here are an essential first step in analyzing
the effect of v-Rel in rodent systems.
Results
v-Rel can be expressed in 3T3 cells after infection with a
retroviral vector
Previous reports (Ge´linas and Temin, 1988; Hannink and
Temin, 1989) failed to detect v-Rel expression in rodent
fibroblasts after stable transfection with cytomegalovirus
(CMV) promoter plasmids or retroviral provirus plasmids.
Consistent with those reports, we found that v-Rel could not
be detected by Western blotting after stable transfection and
G418 selection of pools of 3T3 or Rat-2 cells using a
pcDNA3-based v-Rel expression plasmid (containing the
CMV promoter driving v-rel and the selectable neo gene
controlled by a second promoter) (Fig. 1). In contrast, v-Rel
could be readily detected in extracts from stable pcDNA3-
v-rel transfectants of chicken DF-1 fibroblasts (an immor-
talized chicken fibroblast cell line; Himly et al., 1998) or
D17 dog osteosarcoma cells (Watanabe and Temin, 1983)
(Fig. 1).
Because most studies on v-Rel in avian cells have been
performed with retroviral expression vectors, we sought to
determine whether v-Rel could be expressed in 3T3 cells by
infection with a mouse retroviral vector carrying v-rel. For
these experiments, we first created pMSCV-v-rel in which
v-rel was subcloned into the mouse stem cell virus (MSCV)
vector pMSCV-puro (Hawley et al., 1994). Thus, pMSCV-
v-rel contains v-rel as the 5 gene and the gene for puro-
mycin resistance located 3 to an internal ribosome entry
sequence (IRES) (Fig. 2A).
Viral stocks were prepared for MSCV-v-rel and were
used to infect 3T3 cells, which were then selected for
puromycin resistance for various periods of time. Anti-v-
Rel Western blotting was performed on extracts of pooled
puromycin-resistant cells that had been maintained in cul-
ture for up to 24 days. As shown in Fig. 2B, MSCV-v-rel-
infected 3T3 cells expressed similar amounts of v-Rel
whether assayed after selection with puromycin for 2, 7, 14,
or 24 days. The similar levels of expression of v-Rel in these
cultures at day 2 and day 24 is in stark contrast to what is
seen in rodent fibroblasts after transfection with a plasmid-
based v-Rel expression vector, wherein expression of v-Rel
can be detected shortly after transfection but is absent after
2 weeks of selection (see Fig. 1B above, our unpublished
results, and Hannink and Temin, 1989). 3T3 cells express-
ing v-Rel from MSCV-v-rel were not morphologically
transformed (data not shown).
Indirect immunofluorescence showed that v-Rel was ex-
pressed in the nucleus of MSCV-v-rel-infected 3T3 cells
(Fig. 2C). To ensure that the nuclear v-Rel protein in these
3T3 cells was active, extracts from MSCV-v-rel-infected
3T3 cells were analyzed by an EMSA using a B site probe
from the chicken c-rel promoter that can be bound by v-Rel
(Capobianco and Gilmore, 1991). As compared to control
Fig. 1. v-Rel cannot be detected in Western blots of stably transfected
rodent fibroblasts. The indicated cell types were transfected with
pcDNA3.1 (control empty vector) or pcDNA-v-rel. Cells were then se-
lected with G418 for at least 3 weeks, and extracts containing equal
amounts of protein were analyzed by Coomassie blue staining (A) or
anti-v-Rel Western blotting (B). A molecular weight marker (M) is indi-
cated in kDa. v-Rel (59 kDa) and chicken c-Rel (68 kDa) are indicated by
arrows. NS, nonspecific band that is seen in mouse and rat fibroblasts.
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cells, extracts from these v-Rel-expressing 3T3 cells con-
tained increased B site DNA-binding activity that could be
supershifted by anti-v-Rel antiserum (Fig. 2D). Taken to-
gether, these results demonstrate that nuclear, DNA bind-
ing-competent v-Rel can be stably expressed in 3T3 cells
when introduced by infection with a retroviral vector.
v-Rel does not convert the BaF3 mouse B cell line to
IL3-independent growth
v-Rel was reported to be toxic in primary mouse bone
marrow cells (Schwartz and Witte, 1988). However, avian
cells of the B cell lineage are one of the primary target cells
for transformation by v-Rel and the human c-rel gene is
amplified in many B cell lymphomas (Gilmore, 1999b;
Gilmore et al., 2002). Thus, we were interested in deter-
mining whether MSCV-v-rel could be used to express v-Rel
in murine B cells and whether MSCV-directed expression
of v-Rel would promote the growth of murine B cells.
Growth of the murine pro-B cell line BaF3 is dependent on
interleukin-3 (IL-3); however, BaF3 cells can be converted
to IL-3-independent growth by a variety of oncoproteins. To
determine whether expression of v-Rel could transform
BaF3 cells to IL-3 independence, BaF3 cells were infected
with MSCV-v-rel in the presence of IL-3 and after 4 days
IL-3 was removed. As a positive control, we also infected
BaF3 cells with an expression vector for BCR-ABL, which
has previously been shown to transform these cells to IL-
3-independent growth (Daley and Baltimore, 1988). BaF3
cells infected with MSCV-v-rel did express readily detect-
able amounts of v-Rel when grown in the presence of IL-3
(Fig. 3). However, MSVC-v-rel-infected BaF3 cells did not
convert to IL-3-independent growth, whereas BCR-ABL
expression did transform these cells to IL-3 independence.
v-Rel can be stably expressed in the D17 dog
osteosarcoma cell line either by transfection of a plasmid
vector or by infection with a retroviral vector
In contrast to 3T3 and Rat-2 cells, we found that the D17
dog osteosarcoma cell line could tolerate pcDNA plasmid-
driven expression of v-Rel approximately as well as the
DF-1 chicken fibroblast cell line (see Fig. 1B, and Gilmore,
1999b). As a second means of comparing the levels of
expression of v-Rel between avian fibroblasts and D17 cells,
we infected primary chicken embryo fibroblasts (CEF) and
D17 cells with spleen necrosis virus (SNV) vector MH105
(White and Gilmore, 1996) that contains v-rel as the 5
gene, followed by an IRES and a 3 neo resistance gene (see
Fig. 4A). D17 cells are permissive for SNV replication and
the promoter in the SNV long terminal repeat has been
Fig. 2. v-Rel can be stably expressed in 3T3 cells by infection with a retroviral vector. (A) Bicistronic MSCV-based vector for the expression of v-rel and
the puromycin resistance gene. IRES, internal ribosome entry sequence; LTR, long terminal repeat. (B) Anti-v-Rel and anti-actin Western blotting was
performed on extracts from cells infected with the MSCV vector lacking v-rel (puro) or MSCV-v-rel (v-Rel). Cells were grown in the presence of puromycin
for the indicated number of days. (C) 3T3 cells were infected with MSCV-v-rel and after 4 days were analyzed by indirect immunofluorescence using an
anti-v-Rel primary antiserum. As shown, bright nuclear staining was detected. Uninfected cells in the culture did not visibly stain (not shown). (D) Extracts
were prepared from uninfected (3T3) or MSCV-v-rel-infected 3T3 cells that had been selected with puromycin for 2 or 24 days. An EMSA was then
performed using a B site probe. Where indicated, preimmune (PI) or anti-v-Rel antiserum was also added. The v-Rel-DNA and supershifted complexes are
indicated.
Fig. 3. Expression of v-Rel does not transform the BaF3 mouse B cell line
to growth factor independence. BaF3 cells were infected with MSCV
retroviral vectors for v-Rel or BCR-ABL and were grown in the presence
of IL-3 for 4 days. Cell extracts were then analyzed by Western blotting for
v-Rel or actin. As a control, an extract from 3T3 cells infected with
MSCV-v-rel (for 14 days, as in Fig. 2) was also analyzed on the same gel.
After 4 days, parallel cultures of infected BaF3 cells were deprived of IL-3
and the transformation of the cultures to growth factor independence was
monitored. , IL-3-independent growth; , cells died in the absence of
IL-3.
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shown to work efficiently in D17 cells (Embretson and
Temin, 1987). MH105-infected D17 cultures were selected
with G418 for approximately 3 weeks, and equalized pro-
tein extracts were subjected to Western blotting with anti-
v-Rel antiserum (Fig. 4B). In two separate experiments, we
found that v-Rel was expressed to approximately the same
extent in infected CEF and in D17 cells. For each cell type,
uninfected cells did not express v-Rel. Thus, by infection
with a retroviral vector (Fig. 4B) and by transfection with a
plasmid expression vector (Fig. 1B), v-Rel can be expressed
to approximately the same level in D17 cells and in primary
(CEF) and immortalized (DF-1) chicken fibroblasts.
As shown by indirect immunofluorescence, v-Rel is also
primarily a nuclear protein in DF-1 and CEF chicken cells
and in D17 dog cells (Fig. 4C). In addition, an EMSA using
a B site was performed on extracts from MH105-infected
D17 cells. As shown in Fig. 4D, extracts from D17 cells
show high levels of a B site-binding activity, which is not
present in control uninfected cells and which can be super-
shifted with anti-v-Rel antiserum. Taken together, these
results show that v-Rel localizes to the nucleus as an active
DNA-binding protein in D17 cells.
Expression of v-Rel does not affect the growth rate of
D17 cells
Expression of chicken c-Rel has been shown to arrest
HeLa cells at the G1/S-phase transition point of the cell
cycle (Bash et al., 1997). To determine whether v-Rel af-
fected the growth of D17 cells, we compared the growth
rates of control D17 cells and D17 cells expressing v-Rel
(after transfection with pcDNA3-v-rel and selection with
G418, as for Fig. 1). As shown in Fig. 5, control and
v-Rel-expressing D17 cells grow at essentially identical
rates. Therefore, v-Rel does not appear to affect the growth
of D17 cells, after transfection with a v-Rel expression
vector.
Fig. 4. v-Rel is expressed as a nuclear DNA-binding protein in D17 cells. (A) Structure of spleen necrosis virus vector MH105 (White and Gilmore, 1996).
(B) Anti-v-Rel Western blotting (bottom) of extracts from MH105-infected CEF or MH105-infected D17 cells that had been selected for approximately 2
weeks with G418. In each case, uninfected cells of the same cell type were also analyzed. Chicken c-Rel (68 kDa) and v-Rel (59 kDa) are indicated by arrows.
At the top is a portion of a Coomassie blue stained gel containing same amount of extract used in the Western blot. M, molecular weight markers in kDa.
(C) Indirect immunofluorescence using a primary anti-v-Rel antiserum was performed on the indicated cell types, which had been infected with MH105 and
selected with G418 as described in (B). (D) Extracts were prepared from uninfected or MH105-infected/G418-selected D17 cells and an EMSA using a B
site probe was performed. In the last two lanes, a supershift was performed using v-Rel antiserum, which was added after the DNA-binding reaction. The
bottom panel is an anti-v-Rel Western blot of the extracts from uninfected and MH105-v-rel-infected D17 cells used in the EMSA.
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Discussion
In this article, we show that mouse 3T3 and D17 dog
osteosarcoma cells can sustain high-level expression of v-
Rel, which has previously been reported to be generally
toxic in rodent cell lines (Ge´linas and Temin, 1988; Han-
nink and Temin, 1989; Schwartz and Witte, 1988). Whereas
D17 cells can support expression of v-Rel after either trans-
fection with a plasmid expression vector or infection with a
retroviral vector, 3T3 cells support v-Rel expression only
after infection with an MSCV-based mouse retroviral vec-
tor.
The mechanism by which v-Rel expression is silenced in
mouse and rat fibroblasts after transfection with v-Rel ex-
pression vectors (Hannink and Temin, 1989; Fig. 1, herein)
is not known. Based on cotransfection experiments, it has
been suggested that the lack of sustained v-Rel expression
in these cells is due to a toxicity of v-Rel when its expres-
sion is directed from certain strong promoters (Ge´linas and
Temin, 1988; Hannink and Temin, 1989). Consistent with
this hypothesis, chicken c-Rel, which is highly similar to
v-Rel, has been shown to cause growth arrest at the G1/S-
phase transition in HeLa cells (Bash et al., 1997). Growth
arrest caused by overexpression of chicken c-Rel in HeLa
cells has been correlated with alterations in cell-cycle con-
trol, including increased levels of the Cdk inhibitor
p21WAF1 and p53 (Bash et al., 1997). However, the pos-
sible toxicity of v-Rel in mouse fibroblasts is unlikely to
depend on p53 in that p53-deficient fibroblasts, such as 3T3
cells (Fig. 1B), cannot support v-Rel expression after trans-
fection (data not shown). In addition, high-level coexpres-
sion of the antiapoptotic protein Bcl-2 cannot allow for
sustained v-Rel expression after transfection (data not
shown). Nonetheless, as we now show, MSCV-v-rel-in-
fected 3T3 cells express readily detectable amounts of v-Rel
that do not diminish up to 24 days after infection (Fig. 2B),
and these cells show no apparent growth difference from
uninfected cells (data not shown). Thus, it is not clear
whether the inability of previous experiments to achieve
sustained expression of v-Rel in rodent fibroblasts is due to
the level of expression that is directed by different vectors
or to other differences between the approaches (e.g., infec-
tion vs transfection, sequences in the different mRNAs,
etc.).
In contrast to mouse 3T3 cells and rat fibroblasts, we
show that D17 osteosarcoma dog cells can tolerate sustained
expression of v-Rel after transfection with pcDNA-v-rel;
moreover, D17 cells expressing v-Rel grow at the same rate
as control D17 cells (Fig. 5). D17 cells may have a muta-
tion(s) that allows them to tolerate high-level expression of
v-Rel from these vectors. Alternatively, rodent cells, but not
D17 cells, may have a mechanism(s) to silence expression
from the plasmid-based transfection vectors. That this may,
at least in part, account for the differences between trans-
fected 3T3 and D17 cells is suggested by the observation
that expression of -galactosidase is stable in D17 cells but
not 3T3 cells after transfection and selection with G418
(Fig. 6). Similarly, Hannink and Temin (1989) showed that
v-Rel expression could be detected in the nucleus of Rat-1
cells 2 days after transfection with a CMV promoter-based
vector, but not after 2 weeks of selection. In a cotransfection
assay, the results of Ge´linas and Temin (1988) suggested
that v-rel expression was toxic in Rat-1 cells when ex-
pressed from a strong (MLV) viral promoter but not from a
weak (SNV) viral promoter, whereas D17 cells appeared to
be able to tolerate v-rel expression from either type of
promoter. However, those authors did not directly assess
v-Rel expression in their experiments. In any event, D17
Fig. 6. -Galactosidase can be stably expressed in D17 cells but not in 3T3
cells after transfection with a CMV promoter-based vector. Mouse 3T3 and
dog D17 cells were transfected with a control vector (pcDNA3.1) or a
pcDNA-lacZ vector for the expression of -galactosidase. Cells were then
selected with G418, and pools of cells were analyzed by Western blotting
with an anti--galactosidase antiserum (bottom). The -galactosidase pro-
tein is indicated by the arrow. The top panel shows a Coomassie blue
stained gel of the same amounts of each extract used in the Western blot,
as a loading control.
Fig. 5. v-Rel does not affect the growth of D17 cells. Control D17 cells and
v-Rel-expressing D17 cells (from Fig. 1) were seeded at equal densities in
several plates, and the number of cells in independent dishes was then
monitored each day for 13 days. Cell number versus day after plating is
plotted.
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cells in general appear to be more similar to avian cells,
such as CEF and DF-l cells, which can also support high-
level v-Rel expression from either plasmid or retrovirus
vectors. Moreover, D17 cells, similar to avian cells, can
efficiently support the replication of spleen necrosis virus
retroviral vectors, whereas rodent cells generally cannot
(Embretson and Temin, 1986, 1987).
Although v-Rel is potently transforming in chicken lym-
phoid cells, expression of v-Rel did not transform the mouse
BaF3 pro-B cell line to IL-3-independent growth (Fig. 3). In
addition, Schwartz and Witte (1988) were unable to malig-
nantly transform primary mouse bone marrow cells after
infection with an MLV-based retroviral expression vector.
Therefore, either v-Rel simply cannot transform mouse
lymphoid cells or another factor (e.g., an additional com-
plementing oncoprotein or tumor suppressor) is required for
v-Rel to show transforming activity in mouse lymphoid
cells. Consistent with the latter hypothesis, transgenic mice
in which v-rel is expressed under the control of the T cell
specific lck promoter develop T cell lymphomas only after
approximately 6–10 months, suggesting that other muta-
tions have occurred in these cells (Carrasco et al., 1996).
Indeed, when these lck-v-rel transgenic mice are crossed to
NF-B p50 knockout mice, the T cell lymphomas develop
much quicker (Carrasco et al., 1996), demonstrating that
cellular mutations can enhance the transforming activity of
v-Rel in mice.
In summary, we have created a retroviral vector that can
be used to stably express high levels of v-Rel in mouse cells.
Moreover, we have shown that the restriction to v-Rel
expression that is sometimes seen in rodent cells is not
present in all mammalian cell lines, in that the D17 dog cell
line can support high-level v-Rel expression after transfec-
tion or infection. These studies may be useful in the devel-
opment of mammalian models of oncogenesis induced by
v-Rel or cellular Rel.
Materials and methods
Plasmid constructions
pcDNA-v-rel was created by subcloning an XbaI frag-
ment containing v-rel into the XbaI site of pcDNA3.1. To
construct pMSCV-v-rel, a PmeI fragment containing v-rel
was subcloned at the unique HpaI site of pMSCV-puro
(Hawley et al., 1994; a kind gift of Naomi Rosenberg).
pMH105 has been described previously (White and Gil-
more, 1996).
Cell maintenance and cell growth
All cells (CEF, DF-1, 3T3, D17, Rat-2, BaF3) were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS). For routine
maintenance of BaF3 cells, 0.5 ng/ml of IL-3 (R&D Sys-
tems, Minneapolis, MN) was included.
To compare the growth rates of v-Rel-expressing and
uninfected D17 cells, approximately 10,000 cells of each
cell type were passed into thirteen 60-mm plates. On each
day for 13 days thereafter, the growth was monitored by
counting the number of cells in a single plate after removing
the cells with trypsin-EDTA.
Transfections and infections
To establish stable pools of D17, DF-1, Rat-2, or 3T3
transfectants, cells were transfected using DMSO/polybrene
(Kawai and Nishizawa, 1984) in duplicate 60-mm dishes
with 0.1–0.5 g of pcDNA3.1 or pcDNA-v-rel. The next
day, media was changed to DMEM/10% FBS containing
600 g/ml G418 every 3–4 days thereafter. Fourteen days
later, the G418-resistant cells from each cell type were
passed (as pools) into two 100-mm tissue culture plates.
Cells were allowed to grow until approximately confluent
(3–4 days) and were then processed for Western blotting
or continued passage as described below.
MH105 virus was obtained by harvesting the supernatant
from MH105-transformed chicken spleen cell cultures
(White and Gilmore, 1996). MSCV virus stocks were pre-
pared by transfecting 60-mm plates of 293T cells (DuBridge
et al., 1987) with 15 g of pMSCV-puro or pMSCV-v-rel
plasmid DNA and 15 g of Eco helper virus plasmid DNA
(Muller et al., 1991) by the calcium phosphate method, also
including 50 g/ml chloroquine (Pear et al., 1993). Twenty-
four hours later the transfection mix was removed, and 3 ml
DMEM/10% FBS was added. Over the following 2 days,
media was harvested several times, and virus was pooled
and stored at 80°C.
For infection of D17 and CEF, cells were each passed
into 60-mm dishes at approximately 30% confluency. The
next day, 1 ml of MH105 virus containing 10 g of poly-
brene was added and cells were incubated for 1 h at 37°C.
After 1 h, the media was removed and 3 ml DMEM/10%
FBS was added. 3T3 cells were infected in 60-mm dishes
with 1 ml of MSCV-puro (empty vector) or MSCV-v-rel
virus and 15 g/ml polybrene. Cells were incubated over-
night. The next day media was removed and 3 ml DMEM/
10% FBS was added. The cells were incubated for 2 days in
normal media and then selected with media containing pu-
romycin (2.5 g/ml) as indicated in the text.
For infection of BaF3 cells, approximately 106 cells were
infected with 1 ml of MSCV-BCR-ABL or MSCV-v-rel
virus in medium containing 8 g of polybrene. Cells were
then spin-infected by centrifugation at 1800 rpm for 45 min
at room temperature. An additional 1 ml of DMEM/10%
FBS was then added, including IL-3 to a final concentration
of 0.5 ng/ml, and cells were grown at 37°C. To assay for
conversion of BaF3 cells to IL-3-independent growth, 4
days after infection, cells were pelleted, washed with
DMEM, and then resuspended in DMEM/10% FBS without
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IL-3. IL-3-deprived cultures were then monitored for
growth over the next 10 days (IL-3-independent growth was
seen in BCR-ABL cultures within 5 days of removal of
IL-3).
Western blotting
Cells were either lysed directly in SDS sample buffer or
in AT buffer [20% glycerol; 1% Triton X-100; 20 mM
HEPES (pH 7.0); 1 mM EDTA; 1 mM EGTA; 20 mM NaF;
1 mM Na4P2O7  10 H2O; 1 mM DTT; 1 mM Na3VO4; 1
g/ml PMSF; 1 g/ml leupeptin; 1 g/ml pepstatin] as
described (Gapuzan et al., 2002). Equal amounts of cellular
protein, either judged by Bradford assays (for AT buffer
extracts) or by Coomassie blue staining (of extract aliquots
made directly in SDS sample buffer), were then analyzed by
Western blotting using the following antisera: anti-v-Rel
(1:1000) (Gilmore and Temin, 1986); anti--galactosidase
(1:1500) or anti-actin (1:1000) (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA). Secondary antisera were goat anti-
rabbit-HRP (1:30,000 for v-Rel and for -galactosidase)
and rabbit anti-goat-HRP (1:10,000 for actin). Immunore-
active bands were then detected by chemiluminescence as
described previously (Gapuzan et al., 2002) and as de-
scribed by the manufacturer (Pierce Biotechnology, Inc.,
Rockford, IL).
Indirect immunofluorescence and electrophoretic mobility
shift assays
Indirect immunofluorescence was performed essentially
as described previously (Gilmore and Temin, 1986).
Briefly, 1 day before processing, cells were passed onto
glass coverslips. Cells were then fixed in methanol for 10
min at 20°C. Cells were incubated with primary anti-v-
Rel antiserum (1:40) for 1 h at 37°C and then FITC-conju-
gated goat anti-rabbit antiserum (1:40–1:80; Sigma, St.
Louis, MO). Stained cells were imaged on an Olympus
Confocal microscope.
Electrophoretic mobility shift assays were performed us-
ing a radiolabeled KB site probe from the chicken c-rel
promoter, essentially as described previously (Capobianco
and Gilmore, 1991). Cells were lysed in AT buffer, and 20
g of protein was used in the DNA-binding reactions. For
supershifts, extracts were incubated with 1 l of preimmune
or anti-v-Rel antiserum for 30–60 min on ice before adding
the probe.
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